Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma

NCT06720454 | Completed

• 1 other identifier: YB M-05-01
• Study Type: observational
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC); Molecular Prognostic Model; Regulons

Outcome Measures

Primary Outcomes (1)

• Intensity of immunofluorescence staining

  In this study, 68 pancreatic ductal adenocarcinoma tissues were used to detect the gene expression by multiple immunofluorescence staining

  From January 2019 to January 2024

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

68

You may qualify if:

• Pancreatic ductal adenocarcinoma
• With post-operative paraffin specimens

You may not qualify if:

• Other types of pancreatic cancer other than pancreatic ductal adenocarcinoma
• Without post-operative paraffin specimens or less than 20% of the paraffin sections contain cancerous tissue

Sponsors & Collaborators

• Tiejun Ying: lead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 40030, China

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 1, 2024
• First Posted: December 6, 2024
• Study Start: January 2, 2019
• Primary Completion: February 25, 2020
• Study Completion: April 21, 2024
• Last Updated: December 6, 2024

Record last verified: 2024-12

Locations

CN (1)